- Sarepta Therapeutics Announces Advisory Board Meeting for SRP-9001 | Sarepta Therapeutics, Inc.Investor Relations | Sarepta Therapeutics, Inc.
- Sarepta comes across doubts about drug approval. Buy the stock, analysts say.Barrons
- Sarepta Stock 20% Off FDA Advisory Meeting for its Muscular Dystrophy Treatment (SRPT)Looking for Alpha
- U-turn, FDA orders AdComm for Sarepta’s DMD gene therapyFierceBiotech
- Sarepta slips as surprise FDA panel convenes adds uncertainty for gene therapyReuters
- See full coverage on Google News